Literature DB >> 11592591

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.

K V Menon1, P Angulo, S Weston, E R Dickson, K D Lindor.   

Abstract

BACKGROUND/AIMS: To identify indicators of osteoporosis and to determine the rate of bone loss in patients with primary biliary cirrhosis (PBC).
METHODS: Bone mineral density of the lumbar spine and hip was measured at annual intervals over 7 years of follow-up in 176 patients with PBC.
RESULTS: Osteoporosis (t-score below -2.5) was found in 20% of patients and occurred 32.1 times more frequently in patients with PBC than expected. Patients with histologic stage 3 or 4 disease had a 5.4-fold increased risk of osteoporosis compared to patients with stage 1 or 2. Age, body mass index, advanced stage (3 or 4), and history of fractures were the only independent indicators of osteoporosis. After 3 years of follow up, the rate of bone loss in patients with stage 1 or 2 increased and equaled that seen in patients with stage 3 or 4. Serum bilirubin level was the only variable independently associated with the rate of bone loss over time.
CONCLUSIONS: Severity of the liver disease contributes significantly to the severity of bone disease in PBC. PBC patients who are older, thinner and have more advanced liver disease may have the most benefit from bone density measurements and treatment for their osteoporosis.

Entities:  

Mesh:

Year:  2001        PMID: 11592591     DOI: 10.1016/s0168-8278(01)00144-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  44 in total

1.  Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC).

Authors:  A Floreani
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 2.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

Review 3.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

4.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

5.  Management of liver cirrhosis between primary care and specialists.

Authors:  Ignazio Grattagliano; Enzo Ubaldi; Leonilde Bonfrate; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

6.  Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease.

Authors:  Lu-Qin Bian; Rong-Zhen Li; Zheng-Yun Zhang; Yan-Ji Jin; Hyung-Wook Kang; Zhen-Zhu Fang; Youn-Soo Park; Yoon-Ho Choi
Journal:  J Bone Miner Metab       Date:  2013-04-12       Impact factor: 2.626

7.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 8.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

Review 9.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 10.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.